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Regulation of the Export of Pharmaceuticals to
Developing Countries
Nancy E. Pirt*
It is modern science that has vastly enlarged the scope of modern law. We
have found that the scope of measures necessary for common defense calls
for this enlargement of function. The law has become involved in the necessities of applied science. Is it equal to the task? Will old and settled principles serve? Do the new measures call merely for new applications of old
principles, or for their destruction and the creation of new ones? Is it
merely a changed phase of the conflict between individual liberty and general welfare-between executive discretion and fixed law-between officialism and laissez faire?

J.H.
1.

Wigmore'

INTRODUCTION

In 1915, 100 out of every 1,000 babies born in the United States
would die within the ensuing 12 months. By 1950, this rate had
dropped to 29.2 per 1,000, and by 1978, it was 13.8.2 Consequently,
a child born in the United States in 1978 is expected to live on
average 26 years longer than one born in 1900. The principal factor
in this dramatic increase in life expectancy is the prevention and
control of communicable diseases. Pharmaceuticals, particularly
antibiotics, have played a starring role in this regard. As a result,
the leading causes of death in the United States in 1975 were from
the chronic degenerative diseases-heart disease, malignant neoplasms (cancer) and stroke.4
The situation is quite different in much of the developing world,
*
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1. J.H. Wigmore, Introduction to H.B. HEMENWAY, LEGAL PRINCIPLES OF PUBLIC
HEALTH ADMINISTRATION (1914), as cited by W.J.CURRAN AND E.D. SHAPIRO, LAW, MEDICINE
AND FORENSIC SCIENCE 669 (2d ed. 1970).
2.

U.S. Department of Health and Human Services, Health United States, 1980 at

271, DHHS Pub. No. (PHS) 81-1232.
3.
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where communicable, infectious and parasitic diseases are epidemic.5 The causes of these diseases are no mystery. Inadequate
sanitation, lack of safe drinking water and poor nutrition are all
the sources of disease. The problem is only exacerbated by the inadequate health delivery infrastructures in these countries.'
Pharmaceuticals have the potential to alter this bleak picture considerably. Modern drugs can cure many of the diseases now afflicting the peoples of the developing world, yet the most minimal
7
pharmaceutical needs of these societies go unmet.
The purpose of this article is to explore the role which governmental regulations play in the export of pharmaceuticals to the developing world. The history of Anglo-American pharmaceutical legislation will be traced up to the present day. Next, the
characteristics of the United States pharmaceutical industry will
be examined, as will the characteristics of the market in the developing world. Finally, some possible regulatory responses to the
pharmaceutical needs of developing countries will be offered.
II.
A.

A

HISTORY OF ANGLO-AMERICAN

LEGISLATION

An Overview of Legislation Prior to 1938

Regulation of medicine/pharmacology has a lineage that can be
traced back to ancient Egypt and Biblical times.8 In the history of
Anglo-American jurisprudence, one of the earliest efforts at controlling the practice of medicine was the English Licensure Act of
1511, which required physicians to obtain a license before practicing.9 In 1518, King Henry VIII founded the College of Physicians.10
A few years later, in 1525, a further statute on medical practice
was enacted, mandating that pharmacists accept prescriptions only
from qualified and registered medical practitioners, and further requiring that pharmacists keep these prescriptions on file so that
members of the College of Physicians could review them to determine whether the compounds prescribed were suitable for medical
5. United Nations Centre on Transnational Corporations, TransnationalCorporations
in the PharmaceuticalIndustry of Developing Countries 5 (1984) [hereinafter cited as U.N.
Centre].
6. Id.
7. M. BHAGAT, ASPECTS OF THE DRUG INDUSTRY IN INDIA 11 (1982).
8. Penn, The State Control of Medicine: The First 3000 Years, 8 BRIT. J. CLINICAL
PHARMAC. 293, 293-95 (1979).
9. Cooper, Laetrile-Of Choice and Effectiveness, 38 FOOD DRUG CosM. L.J. 417, 42122 (1983).
10. Penn, supra note 8, at 297.

1987

Pharmaceutical Exports

use.' A later statute, enacted in 1540, gave the College of Physicians the authority to enter apothecary shops and search for drugs
that were "defective, corrupted and not meet nor convenient to be
ministered in any medicine for the health of mans [sic] body."' 2
However, in 1542, Parliament did some de-regulating. Upon observing that licensed physicians were refusing to treat the poor,
Parliament took to task the medical profession for "minding only
their owne lucres [sic]," and for having "troubled and vexed" their
competitors in the practice of medicine, the folk-healers, "honest
men and women whom God hath endowed with the knowledge of
the nature, kind and operation of certain herbs, rootes and
water."" 3 The folk-healers were thereby granted the right to "practise, use and minister in and to any outward sore, uncome, wound,
apostemation, outward swelling or disease, any herb or herbs, oyntments, baths, pultes and emplaisters according to their cunning,
4
experience and knowledge."'
In America, one of the first attempts to proscribe the sale of
fraudulent drugs was made in 1630, when a Massachusetts colonist
was punished for selling a cure for scurvy that the authorities determined to be "a water of no worth nor value."' 5 The regulation of
medical practice and of drugs was to remain within the purview of
local authorities or with the state government for the next several
centuries.
The first federal drug law in the United States was the Import
Drugs Act of 1848,16 which prohibited the import of drugs lacking
in quality or purity, or unfit for medical use. 7 Further federal legislation came in 1906 with the Pure Food and Drugs Act,'" which
prohibited misbranding and adulteration of drugs. However, the
11.
12.
13.
14.

Cooper, supra note 9, at 422.
G. DUKES, THE EFFECTS OF DRUG REGULATION 5 (1985).

Cooper, supra note 9, at 422.
Penn, supra note 8, at 300, quoting G. GOODALL, THE ROYAL COLLEGE OF PHYSICIANS OF LONDON (1684). See also Cooper, supra note 9, at 422. As Cooper observed,
"Quackery thus became the officially sanctioned medicine for the poor." Id.
15. Cooper, supra note 9, at 422.
16. Ch. 70, 9 Stat. 237 (1848).
17. Cooper, supra note 9, at 422. See generally Sonnedecker, Contribution of the
PharmaceuticalProfession Toward Controlling the Quality of Drugs in the Nineteenth
Century, in SAFEGUARDING THE PUBLIC: HISTORICAL ASPECTS OF MEDICINAL DRUG CONTROL 97
(J. Blake ed. 1970).
18. Pub. L. No. 59-384, 34 Stat. 768 (1906). See generally Anderson, Pioneer Statute:
The Pure Food and Drugs Act of 1906, 13 J. PUB. L. 189 (1964); Young, Drugs and the 1906
Law, in SAFEGUARDING THE PUBLIC: HISTORICAL ASPECTS OF MEDICINAL DRUG CONTROL 147
(J. Blake ed. 1970).
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Act of 1906 failed to provide for the review of drugs for efficacy
before distribution.1 9 This loophole was soon the subject of litigation in a prosecution involving a drug called "Dr. Johnson's Mild
Combination Treatment for Cancer, Tumor and Other Chronic
Diseases." In its case against Dr. Johnson, the government argued
that Dr. Johnson had misbranded his drug in violation of the Act
of 1906, because the drug was not effective for treating cancer as it
was touted to be. Mr. Justice Holmes, speaking for the United
States Supreme Court in 1911, rejected the government's position,
the Court instead holding that under the Act, the term "misbranding" meant only the misleading statement of a drug's ingredients,
and not misleading statements as to its effectiveness.2 0 President
William Howard Taft reacted quickly, and within a month of the
Supreme Court's decision, he urged Congress to amend the Act of
1906, stating,
Fraudulent misrepresentations of curative value of nostrums not only operate to defraud purchasers, but are a distinct menace to the public health.
There are none so credulous as sufferers from disease. The need is urgent
for legislation which will prevent the raising of false hopes of speedy cures
of serious ailments by misstatements of fact as to worthless mixtures on
which the sick will rely while their diseases progress unchecked.21

Congress soon amended the statutory definition of "misbranding"
to include false statements of curative or therapeutic effect.22
B.

The Federal Food, Drug and Cosmetic Act

Modern legislation regarding the safety of drugs, on the other
hand, did not come about until 1938. In the 1930's, pharmaceutical
companies were in the business of supplying pharmacists with the
basic array of essential ingredients that were needed to compound
doctors' prescriptions. 2 3 However, the pharmaceutical industry was
19. Cooper, supra note 9, at 422.
20. United States v. Johnson, 221 U.S. 488 (1911).
21. 47 CONG. REc. 2379-80 (1911), as quoted by Cooper, supra note 9, at 423.
22. 37 Stat. 416 (1912) (popularly known as the "Sherley Amendment"), as cited by
Cooper, supra note 9, at 423.
23. G. GEREFFI, THE PHARMACEUTICAL INDUSTRY AND DEPENDENCY IN THE THIRD WORLD
169 (1983).
An illustration of the nature of the industry prior to World War II can be found in this
statement by Harold Clymer, who was employed by SmithKline Corporation during that

time:
R&D as such was nonexistent in most firms ....

[I]t was in 1939 that I joined

SmithKline; you can judge the magnitude of their R&D at that time by the fact that
I was told I would have to consider the position temporary since they had already
hired two people within the previous year for their laboratory and were not sure that
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soon to be transformed with the discovery of the sulfa "wonder
drugs" in the mid-1930's.2 4 In 1936, when the son of President
Franklin Roosevelt was stricken with a streptococcal sore throat,
the nation watched expectantly as the heretofore experimental
drug, prontosil, a type of sulfanilamide, was used successfully to
treat his illness. 25 Shortly thereafter, the Tennessee firm of Massengill & Company marketed a liquid form of sulfanilamide because in the powder form the drug had an unpleasant taste and
precise dosage was difficult to measure.2 6 It was discovered that the
drug would dissolve in diethylene glycol, and soon Massengill introduced its Elixir Sulfanilamide. It is not known whether this
elixir was ever tested for safety in animals or humans; indeed, the
law required no such tests. 27 History does tell us that almost immediately, the American Medical Association (AMA) received numerous reports of possible drug-related deaths from the elixir.
What the chemist who invented the elixir did not know, although
others did, was that diethylene glycol, when ingested, would convert into deadly oxalic acid, a poison that destroys the kidneys. All
told, Elixir Sulfanilamide was blamed for the deaths of 100 people,
mostly children. Included among the death toll was the chemist
who invented the elixir. He committed suicide.2 s
Prior to the sulfanilamide disaster, the Roosevelt administration
had for years been pressing for comprehensive reform of food and
drug legislation, but Congress dragged its feet. 29 Following the disaster, Congress knew that it could delay no longer, and it enacted
the business would warrant the continued expenditure.
INDUSTRY 5 (1983), citing Clymer, The
Economic and Regulatory Climate: U.S. and Overseas Trends, in DRUG DEVELOPMENT AND
MARKETING 138 (R.B. Helms ed. 1975).
24. The discovery of the sulfa drugs was a "spin-off" of research done by Gerhard
Domagk for the Bayer division of the German chemical company, I.G. Farben. At the time,
Domagk was investigating the bacteria-killing properties of dyestuffs. GEREFFI, supra note
23, at 174 n.2.
Many of the large European pharmaceutical companies of the present day originally were
either manufacturers of dyestuffs-e.g., the German company, Hoechst, and the Swiss companies, Ciba-Geigy and Sandoz-or of organic chemicals-e.g., the German company, Bayer,
and the Swiss company, Hoffman-La Roche. Id. at 170-74. The situation is different with
the large United States pharmaceutical companies, most of which originated as pharmaceutical supply houses and for which today pharmaceuticals remain their main products. Id.
25. McDermott, Historical Perspective, in PHARMACEUTICALS FOR DEVELOPING COUNTRIES 9, 12 (National Academy of Sciences 1979).
26. C.H. ASBURY, ORPHAN DRUGS 12 (1985).
27. Id.
28. Id. at 12-13.
29. Id. at 13; Cooper, supra note 9, at 423.
M. STATMAN, COMPETITION IN THE PHARMACEUTICAL
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the Federal Food, Drug and Cosmetic Act.3 0 For the first time in
this country, manufacturers would be required to obtain pre-marketing approval for a drug by submitting to the Food and Drug
Administration (FDA) evidence that the drug was safe. 3 1 The FDA,
however, had to timely act upon the application, within sixty days,
or the drug would automatically become marketable. Once marketed, it was extremely difficult for the FDA to get a drug withdrawn, absent overwhelming evidence of the drug's dangers.32 The
FDA could, however, temporarily extend the review period by requesting additional data on the grounds that the application was
not complete, a contingency which was to figure prominently a few
decades later with thalidomide.
C.

The Kefauver-Harris Amendments of 1962

It was 1956 when thalidomide first went on sale in West Germany. Developed by the West German company ChemieGrunenthal, 33 thalidomide was marketed as a drug to treat vomiting during pregnancy and as a sleeping aid. 34 While thalidomide
was widely available in Europe, it was never approved by the FDA
for marketing in the United States, principally as a result of the
efforts of one person, FDA pharmacologist Frances Kelsey. 5 Kelsey became suspicious of thalidomide after reading a report in the
British Medical Journal which indicated that in a small percentage of patients, there appeared to be a connection between
thalidomide and peripheral neuritis, a "tingling of the nerves," a
side affect which disappeared, however, when the patient ceased
taking the drug. Kelsey called to mind the results of some research
she had done fifteen years before, which showed that drugs which
irritated the nerves in adult rabbits stunted the growth of, and
produced deformities in, the fetuses of pregnant rabbits. Although
there was no evidence that Chemie-Grunenthal had found similar
side effects with thalidomide when tested on rats, mice and other
experimental animals, Kelsey stalled the introduction of
30. Federal Food, Drug & Cosmetic Act, 52 Stat. 1040, 21 U.S.C. §§ 301-392 (1938).
See generally Cavers, The Evolution of the Contemporary System of Drug Regulation
Under the 1938 Act, in SAFEGUARDING THE PUBLIC 158 (J.B. Blake ed. 1970); Young, The
Government and the Consumer: Evolution of Food and Drug Laws-The 1938 Food, Drug
and Cosmetic Act, 13 J. PUB. L. 197 (1964).
31. ASBURY, supra note 26, at 13; Cooper, supra note 9, at 423.
32. ASBURY, supra note 26, at 13.
33. Id. at 25.
34. Penn, supra note 8, at 303.
35. ASBURY, supra note 26, at 24-25.
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thalidomide into the United States market by repeatedly requesting additional information from the drug's American licensee,
Merrell.3 6
The rest of the tragic thalidomide story is generally known. By
1961, an unusual increase in a rare birth defect was being reported
in West Germany. Children suffering from this defect were born
with phocomelia, a condition characterized by foreshortened limbs
and rudimentary hands or feet resembling seal flippers. Where
there had been no reported cases of this particular birth defect in
West Germany during the preceding ten years, suddenly in 1959
there were twelve cases, in 1960, eighty-three, and in 1961, four
hundred and seventy-seven.3 7 The thalidomide tragedy was by no
means confined to West Germany. Some 10,000 infants in twenty
different countries, including Sweden, Italy, Great Britain, Scotland, Switzerland, Lebanon, Israel, Australia, Brazil and Peru were
likewise harmed.3 8 Furthermore, although thalidomide had not yet
been approved for marketing in the United States, it had been distributed by Merrell to more than 1,200 physicians in this country
for clinical testing.3 9 Consequently, a large percentage of the
phocomelia in the United States was seen in children born to the
wives of doctors.4 0
Once again, tragedy mobilized Congress, and the Kefauver-Harris amendments became law.4 These amendments provided for the
abolition of the automatic approval of a drug by default; specified
labeling, package insert and advertising requirements; established
36. M. SILVERMAN AND P.R. LEE, PILLS, PROFITS, AND POLITICS 95 (1974). It was later
found that the laboratory tests performed on pregnant rats, mice and other commonly used
laboratory animals were not enough to uncover the danger of phocomelia. It was only when
the tests were performed on certain species of rabbits that the potential of this birth defect
was shown. Because of the thalidomide tragedy, the FDA today requires that before a drug
can be marketed, its safety in pregnancy must be adequately demonstrated. Id. at 96.
37. Penn, supra note 8,at 299; SILVERMAN AND LEE, supra note 36, at 95.
38. ASBURY, supra note 26, at 25; SILVERMAN AND LEE, supra note 36, at 96.
39. ASBURY, supra note 26, at 26.
40. SILVERMAN AND LEE, supra note 36, at 96.
41. Act of Oct. 10, 1962, Pub. L. No. 87-781, 76 Stat. 780 (codified in scattered sections
of 21 U.S.C.).
Senator Estes Kefauver (D-Tenn.), then chairman of the Senate Subcommittee on Antitrust and Monopoly, originally began his investigation into the pharmaceutical industry in
1959 for the purpose of reviewing the alleged monopolistic pricing practices of the industry.
After the thalidomide incident, drug safety was included in the Amendments. Campbell and
Smith, Profitability and the PharmaceuticalIndustry, in THE PHARMACEUTICAL INDUSTRY
105, 108-09 (C.M. Lindsay ed. 1978).
The co-sponsor of the Amendments was Representative Orren Harris (D-Ark.), Chairman
ofthe House Committee on Interstate and Foreign Commerce. ASBURY, supra note 26, at 27.
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certain quality control measures and record keeping measures; and
required proof of efficacy for all drugs.4 2 Certainly, the most important features of the amendments were those eliminating automatic
approval and requiring proof of efficacy, for now the burden of
proof was upon the pharmaceutical manufacturer and not the
FDA.
The Federal Food, Drug and Cosmetic Act as amended by the
1962 Kefauver-Harris amendments essentially stands as the basis
still for the regulation of pharmaceuticals in the United States.
However, the FDA's policies developed pursuant to the amendments, requiring extensive clinical tests before marketing, have
been criticized as raising the cost of research and development of
pharmaceuticals substantially and as causing a "drug lag" in this
country, i.e., new drugs are said to be introduced in the United
States later than they are in other countries."' Regardless of the
correctness of the drug lag argument, at least one study concluded
that the high standards that the FDA established after the
Kefauver-Harris amendments, rather than hurting United States
manufacturers, have actually turned out to give a competitive advantage by ensuring a reputation worldwide for safety and efficacy.4 4 The subject of the characteristics of the pharmaceutical industry is discussed more fully in section III.
D. Regulation by Executive Order
In October of 1977, the Consumer Product Safety Commission
(CPSC) banned the sale and distribution within the United States
of fabrics treated with the chemical flame retardant TRIS.45 The
ban was based on evidence that TRIS, which was being used to
treat children's pajamas, could be absorbed through the skin and
cause cancer. 4 The CPSC did not attempt to extend this ban to
ASBURY, supra note 26, at 29.
43. See Industry Analysis Division, International Trade Administration, United States
Department of Commerce, A Competitive Assessment of the U.S. PharmaceuticalIndustry
43 (1984) [hereinafter cited as Industry Analysis Division].
FDA officials have vigorously disputed the alleged existence of a "drug lag." Grabowski,
Regulation and the International Diffusion of Pharmaceuticals, in THE INTERNATIONAL

42.

SUPPLY OF MEDICINES 5, 5-6 (R.B. Helms ed. 1980).

44. Industry Analysis Division, supra note 43, at 72, 86.
45. 42 Fed. Reg. 18,850-52 (1977).
46. Comment, United States Export of Products Banned for Domestic Use, 20 HARV.
INT'L L.J. 331, 333 (1979) [hereinafter cited as Comment, United States Export].
For other discussions of the TRIS incident and exports, see generally Agege, Dumping of
Dangerous American Products Overseas: Should Congress Sit Back and Watch?, 19 J.
WORLD TRADE L. 403 (1985); Street, Comment: U.S. Exports Banned for Domestic Use, But
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include the export of TRIS-treated fabrics, since the CPSC did not
believe that its statutory authority encompassed the regulation of
exports.47 Thereafter, the United States manufacturers wasted no
time in shipping the banned pajamas abroad, exporting millions of
dollars worth of the garments to Africa, Asia and South America.48
A few months later, the CPSC, after undergoing a change in its
political makeup, decided that it could, after all, ban the export of
TRIS-treated fabrics, and did so."9
Because of the wide media exposure to the TRIS incident, attention was drawn to the United States' lack of a uniform policy regarding banned products. Accordingly, in May of 1978, President
Jimmy Carter convened an interagency working group 50 to examine this country's export policy and to determine what changes,
if any, were needed. 51 The working group studied the question for
Exported to Third World Countries, 6 INT'L TRADE L. J. 95 (1980-81); Sovereignty vs. Paternalism: The Export of Nonconforming Drugs and Medical Devices, 37 FOOD DRUG COSM.
L.J. 409 (1982); Note, Exportation of Hazardous Products, 7 SYRACUSE J. INT'L L. & COM.
269 (1979-80); Comment, Consumer Safety Abroad: Dumping of Dangerous American
Products Overseas, 12 TEX. TECH. L. REV. 435 (1981) [hereinafter cited as Comment: Consumer Safety Abroad].
47. The statute at issue was the Federal Hazardous Substances Act, as amended (Hazardous Substances Act), 15 U.S.C. §§ 1261-1274 (1979).
48. Comment, United States Export, supra note 46, at 334.
49. 43 Fed. Reg. 25,711 (1978). The CPSC concluded that the Hazardous Substances
Act gave it jurisdiction over any goods originally manufactured for sale in the United States,
but the CPSC still did not believe it could ban the export of goods originally manufactured
and labelled for export. Comment, United States Export, supra note 46, at 334 n.13.
The CPSC stuck with this ban for the next several years, until 1983, when the CPSC
again reversed itself and allowed the export of carpeting which had been recalled for noncompliance with the Federal Flammable Fabrics Act, 15 U.S.C. §§ 1261 et seq. In re Imperial Carpet Mills, Inc., CPSC Docket 80-2 (July 6, 1983). For a criticism of this latest reversal, see Agege, supra note 46.
50. The working group, headed by Esther Peterson, Special Assistant to the President
for Consumer Affairs, included representatives from the Departments of Agriculture, Commerce, Defense, Energy, Health and Human Services (Food and Drug Administration), Justice, Labor, State, Transportation and Treasury. Other members of the working group came
from the Environmental Protection Agency, Consumer Product Safety Commission, ExportImport Bank, Overseas Private Investment Corporation, Action, Agency for International
Development, Regulatory Council, Office of Management and Budget, Council on Environmental Quality, Nuclear Regulatory Commission, Office of the U.S. Trade Representative
and other executive offices. Comment, Consumer Safety Abroad, supra note 46, at 454 n.94,
citing Report of Interagency Working Group on a Hazardous Substances Export Policy
(HSEP), Fifth Draft, July 2, 1980, at 1.
51. Hearings were also convened on this matter in the United States House of Congress. See U.S. Export of Banned Products: Hearings Before the Subcommittee on Commerce, Consumer and Monetary Affairs of the House Committee on Government Operations, 95th Cong., 2d Sess. (1978). The Subcommittee drafted a bill which proposed the
Drug Regulation Reform Act of 1978, see S.2755, 95th Cong., 2d Sess. (1978), which was
modeled after the Medical Device Amendments of 1976, 21 U.S.C. § 381(d)(2) (1976). The
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two and one-half years before making its recommendation to President Carter. 2 Based on the working group's conclusions,5 3 on January 15, 1981, just five days before he left office, President Carter
issued an executive order entitled "On Federal Policy Regarding
the Export of Banned or Significantly Restricted Substances."5 4 As
authority for such an order, the President relied upon the Export
Administration Act of 1979,11 which empowered the President to
establish export restrictions in cases of national security or where
scarce materials were involved or "to the extent necessary to further significantly the foreign policy of the United States or to fulfill its declared international obligations. ' 56 The term "banned or
significantly restricted substance" was defined in the order by reference to seven statutes each of which separately regulated either
food, drugs, chemicals, medical devices or electronics. Essentially,
the order established two methods of regulating the items in question: (a) notification; 57 and (b) export controls for "extremely hazardous substances, '58 for which notification would not provide adeSubcommittee's proposed Act would have permitted the export of unapproved drugs if the
manufacturer first notified the government of the importing country of the drug's unapproved status in the United States. If the foreign sovereign did not disapprove of the importation, the manufacturer could apply for a permit from the FDA allowing the export. This
bill died in committee and never became law. Export Of PharmaceuticalProducts Under
the Federal Food, Drug and Cosmetic Act, 13 CORNELL INT'L L.J. 125, 134-35 (1980).
For a discussion of the export of medical devices under the Medical Device Amendments
of 1976, see Stigi, Greathouse and Dunning, The Federal Drug Administration's Policy in
Relation to the Exportation of Medical Devices, 38 FOOD DRUG CosM. L.J. 193 (1983).
52. 22 HARV. INT'L L.J. 683, 683 (1981).
53. See Background Report On Executive Order 12264 on Federal Policy Regarding
the Export of Banned or Significantly Restricted Substances, 46 Fed. Reg. 7,806 (1981);
Statement on Signing Executive Order 12264, 17 Weekly Comp. of Pres. Doc. 2,909 (Jan. 15,
1981).
54. Exec. Order No. 12,264, 46 Fed. Reg. 4,659 (1981) [hereinafter cited as Carter
Exec. Order].
55. Export Administration Act of 1979, P.L. 96-72, 50 U.S.C. app. §§ 2401-2420 (1979).
56. 50 U.S.C. app. § 2405(a)(1)(1979).
57. Under this notification requirement, the agencies regulating the various products
involved were to send to the Department of State information regarding (a) the name of the
product, (b) a summary of agency action regarding the product and (c) a summary of potential risks to human health, safety or the environment. The Department of State would then
transmit such information to the foreign government importing the product so as to allow
the foreign government to make an informed decision as to whether local conditions within
the country necessitated the use of the product in spite of the potential dangers. 22 HARV.
INT'L L.J. 683, 684-86 (1981).
58. The identification of the "extremely hazardous substances" was to be made by the
agency primarily responsible for regulating the product, upon a finding that (a) the product
was a substantial threat to health, safety or the environment and (b) export would clearly
and significantly harm United States foreign policy interests; licenses for export would be
granted only in exceptional cases. Carter Exec. Order, supra note 54, § 1-301, at 4,662.
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quate protection.

Shortly after taking office, on February 17, 1981, President Ronald Reagan issued an executive order entitled "Federal Exports
and Excessive Regulation," 9 revoking President Carter's order.
The stated goal of President Reagan's order was "to ensure that
the Export Administration Act of 1979 [was] implemented with
the minimum regulatory burden."' 0 As a means of achieving this
end, President Reagan issued an additional executive order,"1 authorizing the Departments of State and Commerce to review current regulatory statutes under a cost-benefit analysis, with the
watchword that regulatory action only be undertaken when "the
potential benefits to society for the regulation outweigh the potential cost to society. 6 2 The FDA has, as a result of this latest executive order, modified some regulations.6 It is possible, although
probably not likely absent specific statutory amendments, 4 that
the FDA may alter some of its export policies governing new, notyet-approved drugs, since the prohibition on the export of unapproved drugs was established by means of an FDA regulation interpreting the Federal Food, Drug and Cosmetic Act.6 However,
the authority of the FDA to extensively repeal its regulatory
framework strictly on the basis of a cost-benefit analysis has been
questioned on the grounds that it is outside of the FDA's statutory
powers to consider matters other than the public health effects.6
These products were then to be placed upon a "Commodity Control List" by the Department of State with the concurrence of the Department of Commerce. It was then up to
these three executive offices to determine if an export license should issue, but only if the
foreign government had raised no objections and if the export would not cause clear and
significant harm to United States foreign policy interests. 22 HARV. INT'L L.J. 683, 685
(1981).
59. Exec. Order No. 12,290, 46 Fed. Reg. 12,943 (1981) [hereinafter cited as Reagan
Exec. Order No. 12,290].
60. Id.
61. Exec. Order No. 12,291, 46 Fed. Reg. 13,193 (1981) [hereinafter cited as Reagan
Exec. Order No. 12,291].
62. Id.
63. See, e.g., 48 Fed. Reg. 27,266 (1983) (withdrawal of proposal for nutrition labelling
of fresh fruits and vegetables); 48 Fed. Reg. 14,000 (1983) (withdrawal of proposed rule
requiring uniform disclosure of the quantity of contents declarations on food, drug and cosmetic labels). For a discussion of Reagan Exec. Order No. 12,291, see Silverglade, The Food
and Drug Administration's Review of Regulations Pursuant to Cost-Benefit Requirements
of Executive Order 12,291, 39 FooD DRUG CosM. L.J. 332 (1984).
64. See generally Halperin, Multinational And International Regulation of
Pharmaceuticalsand U.S. Policy, 17 DRUG INFORMATION J. 153 (1983).
65. See generally Fox and Allard, Exporting United States Pharmaceuticalsin the
1980's, 39 FOOD DRUG CosM. L.J. 411 (1984).
66. Silverglade, supra note 63, at 237-39. See generally Fox and Allard, supra note 65.
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THE PHARMACEUTICAL INDUSTRY

We direct our attention now from the efforts at regulating the
pharmaceutical industry to a look at the industry itself. By appreciating how it is that the industry functions, we can begin to define
the reasons why developing countries are experiencing difficulties
in obtaining pharmaceuticals.
A.

A Profile of the PharmaceuticalIndustry Today

At a time when so many American industries are suffering as a
result of foreign competition, the United States' pharmaceutical
6 7
industry stands out as being highly successful and competitive.
The percentage of exports vis-a-vis domestic sales has risen in the
industry from 6.8% in 1960 to 9.8% in 1979.65 Historically, the industry has shown a surplus in the United States trade balance"9
and, according to figures from 1980, the United States was the
world's largest net exporter of pharmaceuticals. 0 Moreover, the
pharmaceutical industry in the United States is the world's largest
producer of drugs, being responsible for 24.9% of world production
in 1980, just inching out Japan, the number two producer with
23.9% of world production. 71 In terms of world consumption,
America is the second largest consumer, with 25.8% of world consumption. The leader in consumption is Japan, with 26.9% of
7
world consumption. 1
Nevertheless, while American-owned companies are leading in
production, an ever-increasing percentage of this production is being performed by foreign-based subsidiaries of United States par67. Industry Analysis Division, supra note 43, at i.
68. Id. at 19.
69. Id.
70. Id. at 32. Our best customers are Japan, accounting for 21.3'(' of our exports,
France, 8.2"',, West Germany, 5.9,. and Belgium, 5.2%. Id. at 34.
The United States, in turn, purchases 15.4% of its imported pharmaceuticals from the
United Kingdom, 12.9',( from West Germany, 10.0% from Japan, 9.0% from Italy, 8.3%
from Switzerland, 7.3% from Denmark and 5.0% from France. Id.
71. Id. at 30. Notwithstanding its leading position as a producer, Japan actually imports $421.4 million more in pharmaceuticals than it exports, according to figures from
1980-81. Moreover, Japan exports less than 2% of its pharmaceutical production. Id. at 32.
72. Id. at 32. The pattern of consumption for pharmaceuticals is quite different in
Japan from that seen in the United States and Western Europe. Japan has the largest per
capita consumption of pharmaceuticals in the world. Pharmaceuticals make up 40, of Japan's health care expenditures, a figure markedly higher than the 13% averaged by the
United States and Western Europe combined. Only 6% of prescription drugs in Japan are
purchased from pharmacies. The rest come from Japanese doctors, who earn approximately
50% of their incomes by prescribing and dispensing drugs. Id. at 80.
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ent firms. In 1960, sales of overseas subsidiaries as a percentage of
total company sales stood at 20.6%; by 1972, this figure had increased to 32.2% and by 1979 it stood at 41.5%. 7 In fact, for some
United States companies, sales of7 4foreign subsidiaries account for
50% or more of total world sales.
Despite claims to the contrary by some, 75 several industry analysts have concluded that there is no clear cause and effect relationship between FDA regulation and the establishment of foreign
subsidiaries by United States pharmaceutical companies.7 6 Analysts cite other important factors as causing this migration, for example, the pharmaceutical regulation in the foreign market itself.
Some countries, such as Japan, place higher restrictions on drugs
that are not manufactured within their own borders 7 7 or are reluctant to accept the results of clinical trials which were not performed within their country. 78 For these same reasons, foreign
owned pharmaceutical companies have established U.S.-based subsidiaries, since the FDA did not, until recently, accept the results
of clinical trials conducted outside of the United States.7 9 The
move is also seen as part of a more general trend of increased collaboration between American and foreign pharmaceutical
companies.8 0
Today in the United States, there are approximately 1,000 pharmaceutical firms. Only 25 of these firms are United States companies with subsidiaries in foreign countries. 8 ' Another 25 companies
are actually U.S.-based subsidiaries of foreign parent companies.
Notwithstanding their small numbers, these foreign owned, U.S.based companies are responsible for 15% of total sales of
pharmaceuticals in the United States and employ 18% of the
pharmaceutical personnel in this country.8"
73. Id. at 21.
74. Id. at x.
75. See, e.g., Sen. 0. Hatch, Areas for Change in the Food and Drug Laws, 38 FOOD
DRUG CosM. L.J. 97 (1983). Senator Hatch presently has a bill in the Senate proposing some
of the changes to the Federal Food, Drug & Cosmetic Act which he feels are needed to
prevent further pharmaceutical production from going abroad. See infra note 151.
76. See, e.g., Burger, Government Policies and the Development of New Drugs, in
PHARMACEUTICALS IN THE YEAR 2000 at 96 (C. Bezold ed. 1983); Industry Analysis Division,
supra note 43, at 38.
77. Industry Analysis Division, supra note 43, at 81.
78. See generally DUKES, supra note 12, at 16.
79. Grabowski, supra note 43, at 8.
80. Industry Analysis Division, supra note 43, at 38.
81. Id. at 2.
82. Id. However, results of a study done in 1973 indicated that the United States mar-
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The industry is highly competitive in the American market and
no single company accounts for more than 8% of total United
States sales. 8s This reflects a below average concentration of production as compared with such industries as auto, steel, aluminum
or aircraft, placing the pharmaceutical industry in the lowest third
of 450 primary and secondary United States industries rated for
concentration of production.8 '
A key element of competitiveness in the pharmaceutical trade is
the development and marketing of new drugs.8 5 A company makes
most of its money from just a few commercially successful products," which can be eclipsed in the market by the introduction of a
safer, more efficacious drug by a competitor.8 7 Thus, the industry is
characterized by market share instability and continuous entry
into new therapeutic fields. 8
In contradistinction to the diffusion of production facilities
throughout the world, pharmaceutical research typically originates
from one of five countries: the United States, the United Kingdom,
Switzerland, West Germany and Japan. 9 Another hallmark of the
pharmaceutical industry, particularly of the large multinational
firms, is the high level of investment in research and development
(R&D).90 Since the 1960's, global R&D expenditures as a percentage of sales has been around 9%. 91 In 1986, United States manufacturers spent $3.8 billion on R&D, as compared with the $1.8 billion spent in 1980.92 R&D is expensive in part because only 10% to
ket had the least penetration by foreign rivals, at 16% of sales, while the market in the
United Kingdom had the greatest penetration, with 63% of sales going to foreign-owned
pharmaceutical companies, of which 36% was to the U.S.-owned companies. Grabowski,
supra note 43, at 11.
83. Industry Analysis Division, supra note 43, at 3.
84. Id. at 3.
85. Id. at ix.
86. Id. at 24.
87. See Parker, Pharmaceuticalsand Third World Concerns: The Lall Report and
the Otago Study, in THE INTERNATIONAL SUPPLY OF MEDICINES 135, 136 (R.B. Helms ed.
1980).
88. M. STATMAN, COMPETITION IN THE PHARMACEUTICAL INDUSTRY 48, 56 (1983). See
also Conrad, The PharmaceuticalIndustry in the Year 2000, in PHARMACEUTICALS IN THE
YEAR 2000 at 107, 113 (C. Bezold ed. 1983). ("History simply proves that research and development is an elusive temptress that causes yesterday's leading therapy to become just
that-yesterday's leading therapy.")
89. Parker, supra note 87, at 140.
90. Campbell and Smith, supra note 41, at 111; Industry Analysis Division, supra note
43, at viii, 13.
91. Industry Analysis Division, supra note 43, at 39.
92. Cutaia, New Medicines Promise Heady Profits, Bus. WK., Jan. 13, 1986, at 92.
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20% of the drugs that reach the clinical testing stage are actually
marketed.9 s Furthermore, in the United States, the time from basic
research/discovery to FDA approval/marketing can take a decade,
so financial rewards are delayed."4 As of 1984, development costs
for a new drug that ultimately reached the market were as high as
$90-$95 million, 5 although the average cost is more in the range of
$50 million.96
The news is not all bad, however. The pharmaceutical industry
97
also is one of the most profitable of all industries in this country,
as are its counterparts abroad, 98 a fact which has drawn complaints
from some developing countries. 9 During the period from 1958 to
1975, the rates of return for all manufacturing in the United States
averaged 11%, while the rate during the same period for the pharmaceutical industry as a whole was 18.1%, and for the larger pharmaceutical companies, 19.7%. °° Additionally, a unique character93. Industry Analysis Division, supra note 43, at ix. Moreover, if one includes in the
count all of the promising compounds, even those which do not make it as far as the clinical
testing stage, then the ratio of successfully marketed compounds over unsuccessful is only 1
in 10,000. Smith, This Company Could Lead a Revolution in Drugs, Bus. WK., Mar. 24,
1986, at 100.
94. DUKES, supra note 12, at 97. Of this time period, a mean of approximately 2.4
years is taken up in the processing time of an FDA new drug application. Id.
One consequence of this lengthy process has been to decrease the financial rewards of a
patent. Generally, a pharmaceutical company obtains its patent on a potential drug early in
the research process. However, it may be years before the drug reaches marketability, and in
the meantime the life of the patent is elapsing. The longer it takes for the drug to become
marketable, the less time the manufacturer has to recoup his investment from the market.
Kitch, The Political Economy of Innovation in Drugs and Drug Regulation Reform, in THE
INTERNATIONAL SUPPLY OF MEDICINES 74 (R.B. Helms ed. 1980).
95. Industry Analysis Division, supra note 43, at 50.

96.

ASBURY,

supra note 26, at 2.

Industry Analysis Division, supra note 43, at 26.
See DUKES, supra note 12, at 86-87.
See, e.g., Fazal, The Right Pharmaceuticalsat the Right Prices: Consumer Perspectives, in PHARMACEUTICALS AND HEALTH IN THE THIRD WORLD 265 (S. Patel ed. 1983). It
should be noted that the developing countries' complaints regarding pharmaceutical profits
are not directed solely at United States companies but are levied against all of the multinational manufacturers.
97.
98.
99.

100. Measday, The PharmaceuticalIndustry, in
TRY

THE STRUCTURE OF AMERICAN INDUS-

(W. Adams ed. 1977), as cited by Industry Analysis Division, supra note 43, at 26. But

cf. D.

SCHWARTZMAN, INNOVATION IN THE PHARMACEUTICAL INDUSTRY

347 (1976), wherein the

author states that as of 1976, the return on investment for the pharmaceutical industry was
only 3.3',., as compared with 10', for other industries. See also Cuatrecasas, Opportunities
for Research-American Industry, in CONFERENCE ON PHARMACEUTICALS FOR DEVELOPING
COUNTRIES 371 (National Academy of Sciences 1979); D. SCHWARTZMAN, THE EXPECTED RETURN FROM PHARMACEUTICAL RESEARCH 40 (1975).
Schwartzman's results have been questioned, however, as being so low that they do not
make sense, since such results would mean that the pharmaceutical industry has allowed the
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istic of the pharmaceutical market to date has been the apparent
inelasticity of demand for pharmaceuticals in relation to price." 1
Consumers, besides being unaware of price at the time that the
choice of product is made, generally consider price to be less important than quality or availability. 10 2 This picture may be changing, however, with the move even in the industrialized countries to
contain health care costs.'
B.

Great Expectations-The Future for the Pharmaceutical
Industry
The future for the pharmaceutical industry worldwide looks
good, indeed. Earnings in 1986 were expected to be up as much as
13%, reflecting a 10% average increase in prices over 1985 and the
income resulting from the introduction that year of a dozen or so
new products. 0 4 Moreover, it is predicted that global demand for
pharmaceuticals will grow throughout the 1980's at a rate of 10%
to 11 % per year, with real growth of about 3 % to 4 %, for both the
industrialized and the developing world.10 5 Part of this increase is
expected to come about as a result of the nascent biotechnology
industry. ie
return it receives on its capital to fall below its cost of capital. J.W. EGAN, H.N.
HIGINBOTHAM, AND J.F. WESTON, ECONOMICS OF THE PHARMACEUTICAL INDUSTRY 171 (1982).
101. Campbell and Smith, supra note 41, at 111, citing H.S. HOUTHAKKER AND L.D.
TAYLOR, CONSUMER DEMAND IN THE UNITED STATES: ANALYSES AND PROJECTIONS 161-63, 16667 (1970); Industry Analysis Division, supra note 43, at 1.
102. Campbell and Smith, supra note 41, at 111.
103. Industry Analysis Division, supra note 43, at 91-92. See also Cutaia, supra note
92, at 92.
104. Cutaia, supra note 92, at 92. See generally Hamilton, Biotech's First Superstar,
Bus. WK., Apr. 14, 1986, at 68.
105. Industry Analysis Division, supra note 43, at 64. But cf. U.N. Centre, supra note
5, at 3, quoting Gareis and Roepnack, Pharmaceuticalsfor the Third World, in 25 DRUGS
MADE IN GERMANY 48 (1982) ("It looks as if over the next two decades the demand in the
developing countries [for pharmaceutical products] will increase tenfold, while in the industrialized world it will only double or treble.")
106. Industry Analysis Division, supra note 43, at 66-70. The United States government is, by far, the largest investor in biotechnological research when compared with any
other country. In 1983, the United States funded an estimated $511 million in basic research, as compared with $60 million for Japan, $49-70 million for West Germany, $44-60
million for the United Kingdom and $35 million for France. Applied research and development, however, has been funded in the United States by the pharmaceutical industry. Id. at
68.
An.interesting turn in this area of funding came up in connection with the economic summit convened in Tokyo in May, 1986, attended by the United States, Britain, France, West
Germany, Italy and Canada, as well as Japan. The Japanese government suggested that it
would be willing to pay $5 billion over the next decade into a joint research fund, which it
calls "Human Frontiers." The Japanese basically proposed to bankroll the research con-

Pharmaceutical Exports

1987

Yet the significance of the growth in demand for the developing
countries is not certain. In a comprehensive study of the United
States pharmaceutical industry undertaken by the Office of Industry Assessment of the International Trade Administration, (United
States Department of Commerce), the Office reached this conclusion as to the market potential in the developing countries:
The low per capita income of the LDCs [less developed countries], at present, however, does not offer increased opportunities for a significant increase in the sales of pharmaceutical products. Marketing new products
should prove much easier in high-income industrialized countries where the
marketing environment is similar to the U.S.; whereas marketing new products in countries with low per capita income may prove difficult because of
differences in the medical, legal and commercial environments.107

Perhaps a sign of the times for developing countries can be seen in
the 1985 closing by Squibb Corporation of unprofitable operations
in Brazil, Argentina and Uruguay. 10 8
What, then, are these differences in environment which make
the less developed countries a "difficult" market? That is the subject to which we now direct our focus.

IV.

PHARMACEUTICALS AND DEVELOPING COUNTRIES

A.- The Need for Pharmaceuticalsin the Developing World
Out of world sales (at manufacturer's prices) of $80 billion in
1980, it has been estimated that only 20% went to developing
countries, though three-quarters of the world's population lives in
the developing world.10 9 Whereas the developed countries spend
5% of their GNPs on public health expenditures, countries in the
developing world spend little more than 1% of GNP on public
health."10 Moreover, of the money which developing countries
spend on public health, 20% to 40% of the annual budget is spent
on pharmaceuticals, as contrasted with developed countries, in
which pharmaceuticals account for 7% to 12% of health care
ducted by the six other summit countries, in exchange for the right to share in the results of

the research. The research would include such areas as biotechnology and artificial intelligence. It is not at present clear whether the other summit countries can be convinced to
accept such a proposal. It would seem that initial reactions are somewhat wary. N.Y. Times,
Apr. 9, 1986, at A7, col. 1.
107. Industry Analysis Division, supra note 43, at 64.
108. Cutaia, supra note 92, at 92.
109. Peretz, Pharmaceuticalsin the Third World: The Problem From the Supplier's
Point of View, in PHARMACEUTICALS AND HEALTH IN THE THIRD WORLD 259, 259 (S. Patel ed.

1983).
110.

Id.
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costs. 11
In consideration of this disparity, the World Health Organization (WHO) in 1981, at the 34th World Health Assembly, adopted
the Global Strategy of "Health for All by the Year 2000." 12 Indira
Gandhi, then the Prime Minister of India, addressed the opening
session of the Assembly and summed up the position of the developing countries with regard to the multinational pharmaceutical
industry:
Affluent societies are spending vast sums of money understandably on the
search for new products and processes to alleviate suffering and to prolong
life. In the process, drug manufacture has become a powerful industry, subject to the same driving considerations of other big industries, that is, concentration on profit, fierce competition and recourse to hard-sell advertising. Medicines which may be of the utmost value to poorer countries can be
bought by us only at exorbitant prices, since we are unable to have adequate
independent bases of research and production. This apart, sometimes dangerous new drugs are tried out on populations of weaker countries although
their use is prohibited within the countries of manufacture. It also happens
publicity makes us victims of habits and practices which are economically
wasteful or wholly contrary to good health. . . .My idea of a better ordered
world is one in which medical discoveries would be free of patents and there
would be no profiteering from life or death. The world community should
also work some form of recompense for the loss suffered by developing
countries because of this migration of trained doctors and nurses."3

As can be seen from this quote from Gandhi's speech, the dissatisfaction of the developing world with the multinational pharmaceutical industry focuses on three points: (1) marketing practices;
(2) pricing policies; and (3) technology transfer policies. Each of
these points will be addressed in turn.

CAL

111. Drug Distribution and Legislative Problems in the Third World, PHARMACEUTIJ., Nov. 17, 1984, at 618 [hereinafter cited as Drug Distribution and Legislative

Problems]; Jennings, Commentary, in

PHARMACEUTICALS AND HEALTH IN THE THIRD WORLD

151, 151 (S.J. Patel ed. 1983).
112. See generally Note, International Regulation of Pharmaceuticals:A WHO InternationalCode of Conduct for the Marketing of Pharmaceuticals,11 SYRACUSE J. INT'L L.
& CoM. 121 (1984); Note, International Regulation of Pharmaceuticals:The Role of the
World Health Organization, 23 VA. J. INT'L L. 331 (1983).
On a related subject, WHO is also active in setting standards for the marketing of
breastmilk substitutes in the developing countries. For a discussion of WHO's policies in
this regard, see The Implementation Process of the International Code of Marketing of
Breastmilk Substitutes, 11 SYRACUSE J. INT'L L. & Com. 161 (1984).
113. Address by Prime Minister Indira Ghandi, 34th World Health Assembly, as
quoted by S. Patel, Editor's Introduction to PHARMACEUTICALS AND HEALTH IN THE THIRD
WORLD 165, 165-66 (S.Patel ed. 1983).
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B.

Marketing Practices Within Developing Countries

Entire books have been written on the marketing abuses of the
14
multinational pharmaceutical industry in the developing world.'
One cited example pertains to the marketing of the drug lomotil,
used in the treatment of diarrhea. In the United States, lomotil is
available only by prescription and is not recommended for children
because the drug is highly toxic, with the difference between a
proper dose and a fatal one being only slight. The manufacturer
also marketed this drug in Sudan, where it was sold over the
counter. Not only did the package fail to warn of the risks of the
drug, but the label boasted of the product's use by the astronauts
of Gemini and Apollo and went on to recommend the drug for children as young as one year." 5
Another example involves Novobiocin, an antibiotic whose use
was restricted in the United States in 1969 after one in five patients taking the drug had an allergic reaction and because some
patients developed blood disorders from it; Novobiocin continued
to be marketed in Brazil without warnings.11 6 Similarly, the use of
the antibiotic chloramphenicol is restricted in the United States,
West Germany, Denmark and the United Kingdom to life-threatening infections since the drug can cause fatal aplastic anaemia.
However, chloramphenicol is sold over the counter in Mexico with7
out warnings.1
These examples, besides chronicling some of the marketing
abuses by the pharmaceutical industry, also serve to illustrate
some of the marketing problems faced by the industry. It should
be noted that in all of the above examples, the drug in question
had been approved for marketing in the country of manufacture.
Nevertheless, a drug which may be safely administered while
under the supervision of a doctor can be very harmful when marketed in a country where drugs are sold over the counter, some114. See, e.g., M. SILVERMAN, P.R. LEE, AND M. LYDECKER, PRESCRIPTIONS FOR DEATH:
THE DRUGGING OF THE THIRD WORLD (1982); M. SILVERMAN, THE DRUGGING OF THE AMERICAS
(1976); M. SILVERMAN AND P.R. LEE, PILLS, PROFITS, AND POLITICS (1974).

115. Comment, Consumer Safety Abroad, supra note 46, at 437, citing U.S. Export of
Banned Products: Hearings Before the Subcomm. on Commerce, Consumer, and Monetary
Affairs of the House Comm. on Gov't Operations, 95th Cong., 2d Sess. 52-53 (1978) (statement of S. Jacob Scherr, attorney, Natural Resources Defense Council). See also Agege,
supra note 46, at 404.
116. U.N. Centre, supra note 5, at 34.
117. Id. For further examples and discussion, see Silverman and Lydecker, The Promotion of PrescriptionDrugs and Other Puzzles, in PHARMACEUTICALS AND HEALTH POLICY
78 (R. Blum, A. Herxheimer, C. Stenzl, & J. Woodcock eds. 1981).
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times illegally,118 without a doctor's prescription. " ' Additionally, a
drug which might be considered safe for marketing if appropriate
warnings are included may be in practice quite unsafe in a country
such as Colombia, which prohibits the inclusion of package leaflets
with pharmaceuticals, or in Malaysia, where doctors will distribute
drugs directly to the patient by dispensing individual pills or by
giving the patient the entire bottle after all labels have been
removed. 12
The marketing problems of developing countries are made worse
still by a general inability to implement effective pharmaceutical
legislation.' Effective pharmaceutical regulations require a cadre
of highly educated personnel, something which many developing
countries lack. For example, one member of the pharmacy board in
Trinidad and Tobago described pharmaceutical training there as
being in total disarray, with facilities for quality control being nonexistent. 1 22 The West African Pharmaceutical Federation, which
includes members from Gambia, Ghana, Liberia, Nigeria and Sierra Leone, reports that the shortage of pharmacists in that area of
the world is so acute that countries have been forced to allow nonprofessional personnel to dispense drugs. 2 3 Moreover, pharmacists
are needed in governmental health bodies to enforce the licensing
and other requirements of any effective pharmaceutical
legislation. 2 4
No drug is absolutely safe. The meaning of a "safe" pharmaceutical is relative to the circumstances and requires a reassessment of
the risk-benefit analysis in each country, for every drug has inher118.
119.

Drug Distributionand Legislative Problems, supra note 111, at 618.
Melrose, Double Deprivation: Public and Private Drug Distribution From the
Perspective of the Third World Poor, in PHARMACEUTICALS AND HEALTH IN THE THIRD
WORLD 181, 183 (S.J. Patel ed. 1983).

120. U.N. Centre, supra note 5, at 32, 44. Other problems can arise as a result of local
customs, traditions, or even religious beliefs. For example, it has been suggested that in
Moslem countries during Ramadan, which is a 30-day fast during which devout Moslems
will not eat, drink, smoke or allow anything to enter their bodies from sunrise to sunset,
some people may decline to take medicines during daytime fasting. Jouhar, International
Variation in Drug Usage, in INTERNATIONAL ASPECTS OF DRUG EVALUATION AND USAGE 309,

316 (A.J. Jouhar and M.F. Grayson ed. 1973).
121. Restrictions on the Exportation of Hazardous Products to the Third World:
Regulatory Imperialism or Ethical Responsibility?,B.C. THIRD WORLD L.J. 129, 148 (1985).
122. Drug Distributionand Legislative Problems, supra note 111, at 619, citing Dr. Y.
Ali, pharmacy board of Trinidad and Tobago.
123. Id. at 619, citing Dr. James Pearce-Biney of the West African Pharmaceutical

Federation.
124. Id. at 619-620, citing Professor Y.M. Dessouky.
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ent risks, great or small. 125 This is not to suggest that the industry
can be absolved of responsibility for marketing abuses, such as
those noted above, but rather to highlight the complexity of the
problems in marketing.
C.

Price Policies and Developing Countries

Pricing practices raise a different set of issues. The developing
countries, which already have far too little money with which to
buy pharmaceuticals, feel resentful and victimized when they see
the sometimes great disparity in prices for the same drug in different countries. In one study, price variations of up to 600% were
observed among the Andean Pact countries.1 2 6 In a separate study
of the Caribbean market, drugs said to be identical or similar in
effect were compared for price. Differences of between 50% to
27
5000% were reported to have been found.1
Price variations between countries are explained by the industry
as being the result of factors such as regional price controls and
freezes, currency devaluations, taxes, retail versus wholesale margins and other market factors."2 8 The primary concerns of the developing countries, however, are with the matter of "transfer pricing," where the price goes up with each sale between subsidiaries
of the same company.
In an effort to improve their purchasing power, developing countries are pooling their drug purchases into one order to lower the
manufacturer's overhead costs and to take advantage of wholesale
pricing. Other countries are buying their pharmaceuticals in unpackaged, bulk orders and are completing the packaging process
themselves as a way of lowering costs. 2 9 Yet another approach to
make drugs more affordable for developing countries is the World
Health Organization's list of 200 essential drugs. The list is meant
to assist developing countries in choosing their purchases carefully
so as not to waste resources on drugs which have limited health
value.13 0 To this end, one manufacturer, Ciba-Geigy, has begun
125. U.N. Centre, supra note 5, at 31.
126. Id. at 15.
127. Von Wartensleben, Major Issues Concerning Pharmaceutical Policies in the
Third World, in PHARMACEUTICALS AND HEALTH IN THE THIRD WORLD 169, 171 (S.J. Patel ed.
1983).
128. Speech by Klaus M. Leisinger, representative of Ciba-Geigy, Use of
Pharmaceuticalsin the Third World: An Industry Perspective, HARVARD SCHOOL OF PUBLIC
HEALTH, TAKEMI FORUM (Mar. 6, 1986); U.N. Centre, supra note 5, at 16.
129. Von Wartensleben, supra note 127, at 171-72.
130. Fattorusso, Essential Drugs for the Third World, in PHARMACEUTICALS AND
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marketing an inexpensive, generic line of the drugs included on the
WHO list.'3 '
D.

Technology Transfer Policies

The third category of complaints raised by the developing countries pertains to technology transfer policies. The countries of the
Third World would like to get out of the position of depending
upon imports for their pharmaceutical needs. To accomplish this
goal, some countries have tried the approach of limiting a manufacturer's patenting rights. For example, Argentina, Colombia and
Egypt only allow patents on the manufacturing process, and not on
the product itself. Other countries, such as Brazil and Korea, issue
no patents at all.132 The drawback of such approaches, it would
seem, is that these policies would deter the introduction of the latest and perhaps most desired drugs in that market.' 33 A different
tactic is taken by India and Costa Rica, which have established
compulsory licensing requirements, setting up a royalty arrange34
ment with the pharmaceutical company.
Yet, still other problems have arisen in connection with attempts
by developing countries at establishing their own pharmaceutical
plants. Local production has not always proven to be cheaper, and
there have been difficulties in maintaining quality."15 Moreover,
countries in the developing world often do not have the technically
trained personnel to operate these plants. On this latter point,
many of the multinational companies have been making some efforts to help. For example, Ciba-Geigy has started a school for laboratory technicians in Indonesia and a research center/technical
HEALTH IN THE THIRD WORLD 177 (S.J. Patel ed. 1983).

131. Leisinger, supra note 128.
132. U.N. Centre, supra note 5, at 46.
133. The Reagan Administration is not happy with the countries that do not honor
patents or copyrights. For this reason, the Administration has recently threatened to take
back the preferential tariff status of several countries, including Argentina, Brazil, Singapore, Taiwan and Thailand. Additionally, the Administration wants to amend the Trade Act
of 1974 to make it easier to retaliate against illegal imports by lifting the evidentiary requirement that companies prove that they have been injured. The Administration is also
looking to use its influence at the World Bank and the International Monetary Fund to put
pressure on the countries to crack down on patent infringements, and there are plans to
include reciprocal patent protection on the agenda of the next round of talks on the General
Agreement on Tariffs & Trade. Reagan Turns Up the Heat on Patent-PilferingCountries,
Bus. WK., Apr. 21, 1986, at 47.
134. Id. at 46.
135. Treharne, Commentary, in THE INTERNATIONAL SUPPLY OF MEDICINES 153, 155 (R.
Helms ed. 1980); Leisinger, supra note 128.
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school in India. Additionally, Ciba-Geigy and another Swiss company, Hoffman-La Roche, have jointly set up a research and training center in Tanzania for tropical diseases. Similarly, ten United
States companies are working with the government of Gambia in
conjunction with Africare to improve that nation's health care system. More generally, the American company SmithKline & French
is financing the production of educational material in Zimbabwe to
13
assist village health workers.
Certainly, these efforts will help, but still the health problems of
the developing world persist. Moreover, as portended by the Industrial Analysis Division report, supra section IIIB, the developing
countries stand to be left behind in the biotechnical revolution. It
has been said that while current antibiotics and vaccines are capable of curing the communicable diseases-smallpox, measles, polio,
rheumatic fever and pneumonia-these traditional therapies will
not eliminate the major infectious or parasitic diseases which
chronically afflict almost one billion people.1 37 Biotechnology, specifically recombinant-DNA (r-DNA) techniques, are seen as the
only means of developing vaccines to eliminate these health
hazards, yet commercial development of such vaccines is not following technological breakthroughs.' 38 As of 1982, only 1% of all
federally funded research projects in the United States were look13 9
ing into vaccine development.
What sort of regulatory frameworks might be used to assist the
developing world with its health needs? Some possibilities will be
explored, infra, in section V.
V.

RECOMMENDATIONS

The health needs of the developing world are readily apparent.
Insofar as pharmaceuticals can alleviate these needs, the focus of
136.
137.

Drug Distribution and Legislative Problems, supra note 111, at 618.
Lappe', Biotechnology's Debt to Public Health, TECH. REV., Aug./Sept. 1985, at

14.
138. Id.
139. Id., citing a 1982 survey performed by the Smithsonian Science Information Exchange. But cf Conrad, supra note 88, at 115, wherein the author, who is Vice President for
Pharmaceuticals and a member of the Executive Committee and Board of Directors for
Hoffman-La Roche, predicts:
Because of its potential to facilitate the development of exceptionally pure antibodies, rDNA technology may stimulate a reemergence of vaccine research. Presently,
only a few companies are involved in such research, primarily because of long-term
liability problems associated with the difficulties in achieving sufficiently pure products. As rDNA eliminates many of the problems of producing highly purified vaccines
on a broad scale, more companies will again enter this research area.

Duquesne Law Review

Vol. 25:255

United States regulations must be on both the necessity of encouraging R&D of future useful pharmaceuticals and on the necessity
of getting currently available pharmaceuticals to the developing
world.
One possibility for encouraging R&D in this area might be found
in the Orphan Drug Act ' enacted by the United States Congress
in January of 1983. Implicit in the Orphan Drug Act is the acknowledgement that while the United States pharmaceutical industry might be considered to be a highly regulated industry, it is,
nevertheless, made up of privately owned, as opposed to governmentally operated, companies, in business for a profit. Thus, an
"orphan drug" is a drug that, while medically important, is financially unprofitable for the pharmaceutical industry to develop.
There are several reasons why a drug may be unprofitable, such as:
(a) the drug is not patentable; (b) the drug is highly toxic, e.g.,
cancer treatments, and companies may decide that the potential
earnings do not outweigh the potential liabilities; (c) the drug is for
a rare disease and, ergo, a small commercial market; or (d) the
drug has been approved for one particular use and it is later discovered to be effective for another disease which is more rare."
To encourage research and development of such drugs, the Orphan Drug Act allows for special financial incentives in the form of
tax credits equaling 50% of clinical testing expenses,"" grants to
cover qualified clinical testing, 4 3 and exclusive seven-year market44
ing rights for unpatentable drugs.1
While the Orphan Drug Act was not drafted with a mind toward
the problems of the developing world, it nevertheless would seem
to have some potential for application in this area, an idea which
has been recognized by some. 45 For example, Ciba-Geigy's U.S.based subsidiary 146 has obtained an Orphan Drug designation from
140. Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049 (1983) (codified as amended
in scattered sections of 21 U.S.C., 26 U.S.C., and 42 U.S.C. (1982)). For other discussions
about the Orphan Drug Act, see generally ASBURY, supra note 26; Grossman, The Orphan
Drug Act: Adoption or Foster Care?, 39 FooD DRUG CosM. L.J. 147 (1984); Note, Orphan
Drugs: The Question of Product Liability, 10 AM. J.L. & MED. 491 (1985).
141. ASBUav, supra note 26, at 3. For a discussion of the costs of research and development, see supra notes 81-87 and accompanying text.
142. 26 U.S.C. § 44H (1984) (renumbered and amended at 26 U.S.C. § 28 (Supp.
1986)).
143. 21 U.S.C. § 360ee ( Supp. 1986).
144. 21 U.S.C. § 360cc (Supp. 1986).
145. ASBURY, supra note 26, at 194-95. See also Lappe', supra note 137, at 78.
146. Ciba-Geigy Corp. is a Swiss company. For a discussion of the origins of CibaGeigy see supra note 24.

1987

Pharmaceutical Exports

the FDA for clofazimine (Lamprene), a drug for the treatment of
leprosy. Within the United States, there is a small (around 5000)
but growing number of cases of leprosy among the community of
recent immigrants from areas of the world such as southeast Asia
and Latin America.1 47 Clofazimine, although being developed for
the United States market under the umbrella of the Orphan Drug
Act, could have a wider application in the developing nations
where leprosy is more of a problem.14"
Nevertheless, as it stands, the Orphan Drug Act has not alone
satisfied the pharmaceutical needs of developing countries.
Stronger incentives in the form of tax breaks or government grants
towards the required R&D could be specifically targeted for work
on the infectious and parasitic diseases now afflicting almost 1 bil149
lion people worldwide.
The Orphan Drug Act, or an equivalent statute drafted with a
mind toward the Third World, could help to encourage research
and development for new drugs and biotechnologies to be applied
in developing countries. 50 Still, there are many drugs already
available which can alleviate morbidity and mortality in developing countries. The Orphan Drug Act will not affect the distribution
of these latter products. The problem here is not the absence of
interest by the pharmaceutical industry in the necessary research
and development work, but rather a lack of money on the part of
the developing world with which to purchase pharmaceuticals. The
United States government could promote interest by the pharmaceutical industry in the market in developing countries by making
certain that a sufficient percentage of the United States' foreign
aid money to the Third World is designated for the purchase of
essential pharmaceuticals.
It is sometimes suggested that the export of pharmaceuticals
should not be regulated at all, and that the decisions regarding a
147. Leisinger, supra note 128. See also ASBURY, supra note 26, at 194-95.
148. Leisinger, supra note 128; ASBURY, supra note 26, at 194-95.
149. Lappe', supra note 137, at 14.
It is to be noted that not all have agreed with the use of the Orphan Drug Act for diseases
rare in the United States but prevalent in other countries. See, e.g., Grossman, supra note
140, at 131 n.20. In fact, the FDA has itself considered issuing a regulation which would
grant orphan drug status only to pharmaceuticals targeted at diseases which affect at least
500 people in the United States, the rationale being to protect against "subverting" the Act.
See ASBURY, supra note 26, at 182-83. However, as pointed out by one author, the report of
the House of Representatives which accompanied the bill advancing the Orphan Drug Act
indicated that the House viewed any efforts at developing drugs needed in other countries
as being in the public good.
150. Lappe', supra note 137, at 78.
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drug's safety and efficacy should be left to the importing country. 151 Under the present state of the law, United States pharmaceutical manufacturers may not export from this country drugs
which have not been approved by the FDA, with a limited exception for experimental drugs.
There are basically three different ratings of drugs for marketing
approval. The first is approved, which means that the drug can be
marketed in the United States or abroad. The second is unapproved, which means that this drug has neither been approved nor
disapproved by the FDA. This could mean either that the manufacturer has not applied for approval, or that it applied but withdrew its application, or that the application is pending before the
FDA. The third is nonapproved, or banned, which means that the
FDA has reviewed the application but has refused permission to
market the drug because it was found to be not safe or effective.' 52
Only approved drugs can be exported from the United States, and
this includes drugs supplied to developing countries through the
153
Agency for International Development (AID).
Manufacturers argue that it is paternalistic of the United States
to prohibit all export of unapproved drugs and they argue for a
policy of unregulated export of pharmaceuticals. This simply is not
a creditable position vis-a-vis the developing world. As discussed
previously, many developing countries lack sufficient numbers of
the highly educated personnel needed to establish meaningful review of pharmaceuticals. If the United States export law is pater151. On October 18, 1986, the United States Senate and the House of Representatives
unanimously passed an omnibus health bill. S. 1744, 99th Cong., 2d Sess. (1986). One subsection of this bill would allow U.S. pharmaceutical manufacturers to export pharmaceuticals which are awaiting approval in the United States to medically sophisticated countries in
which these pharmaceuticals have already been approved. The stated purpose of this bill is
to safeguard the scientific advances of the emerging biotechnology industry and to keep jobs
and technology in the United States. This bill has yet to be signed by President Reagan.
152. AsBuRY, supra note 26, at 184.
153. Id. The total amount of federal assistance to developing countries via AID will
amount to $600 million in 1986. Private foundations in the United States also contribute
financial support to efforts to promote economic and social development in the developing
world. For example, the Rockefeller Foundation recently expanded its program of global
aid, with plans to spend as much as $300 million over the next five years. A specific focus of
the Rockefeller Foundation program is the implementation of biotechnological discoveries,
such as vaccines and improved contraceptives, in Third World countries. N.Y. Times, May
4, 1986, at A24, col. 1.
Other private foundations which supply aid to developing countries include the Ford
Foundation, which contributes $60 million annually to this cause, the Carnegie Corporation,
with $10 million in annual contributions and the Kellogg Foundation, also contributing $10
million annually. Id.
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nalistic, then it is a case of responsible paternalism.
Moreover, there is a trend among other industrialized countries
to move toward more restrictive pharmaceutical regulations, not
less. 154 For example, in West Germany, drugs already on the market are being reconsidered, and as a result, in 1984, 171 drugs were
recalled from the market. 155 This trend should only intensify as the
biotechnologically produced drugs enter the market. 58 As the Industry Analysis Division concluded in its study of the pharmaceutical industry:
Perhaps the most important implication of the future competitive environment, however, is the potential impact on regulatory requirements resulting
from the emergence of new classes of drugs. Not only will these drugs touch
on the most personal and sensitive aspects of an individual's life (mental
functions, reproductive systems, etc.), and hence raise special concerns for
drug safety, but some will raise ethical and societal issues that may be more
far-reaching than current arguments about safety and efficacy ...

Society

will resist leaving decisions on the development and distribution of such
drugs to the marketplace, based only on criteria of economic efficiency.
Pressures for regulation, moreover, will come from all sides of the political
spectrum-from the right as well as the left. Thus, while there are some
forces at work to reduce the level of government regulation over drug development and.marketing, the convergence of concerns related to safety and
societal impact as these new drugs emerge will create pressures for more,
rather than less, government regulation. 57

It would therefore seem inappropriate to deregulate exports to developing countries.
In summary, regulation for the developing countries should address both the need to get currently available pharmaceuticals to
the developing world and the need to encourage research into future useful pharmaceuticals. It was suggested that the United
States government should ascertain that a sufficient percentage of
its foreign aid is specifically designated for the purchase of essential pharmaceuticals for the developing countries. It was also suggested that the Orphan Drug Act, or an equivalent statute, could
do much to encourage future research for these projects. These
measures alone will not solve all of the health problems of the de154. Industry Analysis Division, supra note 43, at 73, 92. See also DUKES, supra note
12, at 25-28.
155. Industry Analysis Division, supra note 43, at 73.
156. Industry Analysis Division, supra note 43, at 92. See also Bezold, Pharmaceuticals in the Year 2000: An Overview, in PHARMACEUTICALS IN THE YEAR 2000 at 1, 7-9 (C.
Bezold ed. 1983). See generally Biotechnology in the Manufacture of Pharmaceuticals:The
Need For InternationalRegulation, 19 TEx. INT'L L.J. 675 (1984).
157. Industry Analysis Division, supra note 43, at xiv (emphasis in original).

282

Duquesne Law Review

Vol. 25:255

veloping world, absent improvements in the conditions within
those countries, but such measures will still go a long way towards
assisting those countries with their critical health problems.
VI.

AUTHOR'S POSTSCRIPT

Since the completion of the preceding article by this author,
President Reagan has, on November 14, 1986, signed into law an
omnibus health bill, included in which was the Drug Export
Amendments Act of 1986.158 The Drug Export Amendments Act
significantly changes the Federal Food, Drug and Cosmetic Act in
that the amendments for the first time permit the export of unapproved drugs, while an application for approval is pending, to certain developed countries if those countries have already approved
the drug in question.
The Drug Export Amendments Act also addresses itself in part
to the health problems of the developing world. The amendments
allow for the export of an unapproved drug for the prevention or
treatment of a tropical disease if it can be shown that the drug
would be safe and effective in the country importing the drug.
Another significant provision of the Drug Export Amendments
Act comes as an amendment to section 241 of the Public Health
Service Act,159 adding this section: "The Secretary may conduct biomedical research, directly or through grants or contracts, for the
identification, control, treatment, and prevention of diseases (including tropical diseases) which do not occur to a significant extent
in the United States."16 0 Thus, with the Drug Export Amendments
Act, the Congress has expressed its support for biomedical research
to alleviate the health problems endemic to the developing world.

158. Act of Oct. 18, 1986, Pub. L. No. 99-660, 132 Cong. Rec. H-11594 (daily ed. Oct.
17, 1986).
159. 42 U.S.C. § 241 (Supp. 1986).
160. Act of Oct. 18, 1986, Pub. L. No. 99-660, § 104(c), H-11594-96 (daily ed. Oct. 17,
1986).

